Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$8.51 - $13.6 $159,034 - $254,156
-18,688 Reduced 19.15%
78,880 $827,000
Q2 2022

Aug 12, 2022

BUY
$7.31 - $11.85 $713,222 - $1.16 Million
97,568 New
97,568 $944,000
Q3 2019

Nov 13, 2019

SELL
$29.87 - $42.22 $953,868 - $1.35 Million
-31,934 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$31.16 - $39.46 $91,641 - $116,051
-2,941 Reduced 8.43%
31,934 $1.26 Million
Q1 2019

May 13, 2019

BUY
$19.96 - $38.62 $696,105 - $1.35 Million
34,875 New
34,875 $1.35 Million

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Eam Investors, LLC Portfolio

Follow Eam Investors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Investors, LLC with notifications on news.